pharmaci world flat
thesi updat entir rx suppli chain felt toxic
past month pharmaci suffer
retail apocalyps met reimburs armageddon lead
flat ep growth next two year stun
develop show happen solid manag
massiv cost cut effort help blunt assault ultim
investor want see gp stabil seem near
even medium term event furthermor action creat digit
enterpris need probabl bit late overal downsiz
industri box perspect desper requir
highli uncertain make challeng combin
addit given underli profit uncertainti larg transact
may prove challeng take leverag elev
includ oper leas isnt necessarili prudent get clariti
key existenti threat opioid rebat thu
littl get excit forese futur
thank yield hsd near somewhat limit
downsid reiter rate overal view
complex remain skeptic best
model/pt updat lower ep across board given underli
profit challeng return msd growth primarili
result cost cut repurchas dcf impli margin
degrad termin year growth roughli flat
thereaft impli pt place pt
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
ep roughli flat constant currenc basi
gm remain pressur us
reimburs pressur unlik chang take time mitig plan
kick
uk market condit weak
bonu payment estim substanti reduc
manag program track contribut alreadi assum
lap
advers reimburs pressur impact revenu
invest bn next year
rate cash flow gener bn
vs bn guidanc origin contribut ep growth
anticip growth oper
growth flat due revers benefit payment
repo bn per year ep growth
tax expect increas bp headwind
oper expens
invest mm partnership digit
havent built partnership guidanc
year bn headwind
capital-expenditure mm higher run rate convers store
month week assess phase
complet better idea
increas goal bn
suppli cost quartil
spend peer set
new field manag structur us
combin team
implement complet begin june
opportun reduc spend mm
opex capital-expenditure split
select invest part save increas digit offer
project need drive increment benefit
close store
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti on-line competit amazon erod front end comp margin us
pharmaci share continu reimburs pressur us eu hit ultim lead total margin compress
transact prove challeng increas volum /revenu store appear futil lead poor return
posit independ retail us becom disadvantag vertic integr peer capabl take notabl
share manag unabl locat creativ transact leav balanc sheet underutil limit total oper
growth beauti push ultim becom distract momentum build manag must revisit costli rebuild
laboratori corp america
articl articl
time dissemin april
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
